Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three-year Pap screening interval carries low risk

This article was originally published in Clinica

Executive Summary

A US study has provided more evidence to validate lengthening the interval between cervical cancer screening tests to three years. The study of 1.2 million screening result records found that women over 30, who have had three consecutive negative Pap smears, incurred very little risk if the screening interval was lengthened from one year to three years. The findings back the decision by the US National Breast and Cervical Cancer Early Detection Program to lengthen the screening interval of enrolled women with multiple consecutive Pap tests. The study is published in The New England Journal of Medicine (October 16).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT065125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel